These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38290205)

  • 21. Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan.
    Otsuru M; Yanamoto S; Yamada SI; Nakashiro K; Harazono Y; Kohgo T; Nakamura M; Nomura T; Kasamatsu A; Tanaka S; Kirita T; Kioi M; Ogawa M; Sasaki M; Ota Y; Umeda M
    Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
    Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
    Gao A; Pan X; Yang X; Lin Z
    Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
    Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
    Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
    Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome.
    Röhl L; Wellhausen J; Berszin M; Krücken I; Zebralla V; Pirlich M; Wiegand S; Dietz A; Wald T; Wichmann G
    Front Immunol; 2023; 14():1237623. PubMed ID: 37849764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
    Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
    Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
    Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
    In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
    Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study.
    Cheng L; Chai C; Liu Y; Jiao J
    Oncol Lett; 2024 Aug; 28(2):352. PubMed ID: 38872864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma.
    Chang KP; Wu CC; Fang KH; Tsai CY; Chang YL; Liu SC; Kao HK
    Oral Oncol; 2013 Aug; 49(8):802-7. PubMed ID: 23769451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
    Chen TC; Wu CT; Wang CP; Hsu WL; Yang TL; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2015 Nov; 51(11):1004-1010. PubMed ID: 26365985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.